Epidermolysis Bullosa (EB) Clinical Trials and Treatments

Epidermolysis bullosa (EB) comprises a group of genetic blistering disorders caused by mutations affecting structural proteins anchoring the epidermis to the dermis at the dermal-epidermal junction. The condition presents with fragile, blistering skin that tears easily with minor trauma. Three major groups are recognized: EB simplex (usually mild, intraepidermal blistering), junctional EB (intermediate to severe, blistering at the basement membrane zone), and dystrophic EB (severe, subepidermal blistering with scarring).

The most common symptoms of Epidermolysis Bullosa include Blistering and erosions of skin from minimal trauma, Severe itching and pain, Scarring and contractures limiting mobility, Nail dystrophy and loss, Involvement of oral mucosa, esophagus, and GI tract, among others. Epidermolysis Bullosa affects approximately 1 in 50,000 births; approximately 25,000-30,000 Americans affected. Symptoms can range from mild to severe and may vary between individuals.

Trial Friend lists all active clinical trials for Epidermolysis Bullosa from ClinicalTrials.gov, with eligibility criteria translated into plain English. Patients can filter by trial phase and recruitment status, search by location, and use the Match Me tool to score trials against their profile. Gene therapy for epidermolysis bullosa is one of the most promising emerging therapies for genetic skin diseases. Clinical trials are evaluating ex vivo gene therapy (using patient's own keratinocytes genetically corrected ex vivo, then grafted back) and in vivo approaches.

Yes. As of September 2026, Trial Friend lists 3 FDA-approved drugs used to treat Epidermolysis Bullosa: Vyjuvek (beremagene geperpavec-svdt), first approved in 2023; Filsuvez (birch triterpenes), first approved in 2023; and Zevaskyn (prademagene zamikeracel), first approved in 2025.

Each has its own page with what the label covers, side effects and how it is given, and the Treatments section of this page adds any further approved drugs found in FDA labeling data.

Epidermolysis Bullosa is caused by variants in any of many genes, most often COL7A1, KRT5, KRT14, LAMB3, COL17A1 and LAMA3. Dystrophic EB is COL7A1 (dominant or recessive), EB simplex is mostly KRT5/KRT14 (dominant), and junctional EB is laminin-332 or COL17A1 genes (recessive).

It follows autosomal dominant or recessive depending on type inheritance. The condition affects approximately 1 in 50,000 births; approximately 25,000-30,000 Americans affected. A multigene panel identifies the cause in most families.

Yes. Epidermolysis Bullosa can be caused by variants in many different genes (COL7A1, KRT5, KRT14, LAMB3, COL17A1 and LAMA3 are among the most common), so testing is usually a multigene panel or exome sequencing rather than one gene at a time. Dystrophic EB is COL7A1 (dominant or recessive), EB simplex is mostly KRT5/KRT14 (dominant), and junctional EB is laminin-332 or COL17A1 genes (recessive).

It follows autosomal dominant or recessive depending on type inheritance.

Knowing the exact gene matters: it decides which trials a patient qualifies for and which relatives should be tested. The labs currently offering the test are listed in the Genetic Testing section of this page, pulled live from the NIH Genetic Testing Registry. A genetic counselor can help interpret the result and decide which relatives should be tested.

Eligibility for Epidermolysis Bullosa clinical trials depends on factors like age, diagnosis, treatment history, and overall health. Each trial sets its own inclusion and exclusion criteria. Trial Friend translates these requirements from medical language into plain English so patients can review them more easily. The Match Me tool can score your profile against active trials to help identify studies that may be a fit.

Participating in a Epidermolysis Bullosa clinical trial typically involves scheduled visits, medical tests, and close monitoring by a research team. Depending on the study phase, you may receive an investigational treatment, a placebo, or the current standard of care. Trials may last from a few weeks to several years. Study participation is voluntary, and you can withdraw at any time.